Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational drug discovery: Ellagic acid as a potent dual-target inhibitor against hepatitis C virus genotype 3 (HCV G3) NS3 enzymes.

Chemical biology & drug design - 1 Jan 2021

Lim See Khai, Othman Rozana, Yusof Rohana, Heh Choon Han

Abstract excerpt

Structure-based virtual screening (SBVS) has served as a popular strategy for rational drug discovery. In this study, we aimed to discover novel benzopyran-based inhibitors that targeted the NS3 enzymes (NS3/4A protease and NS3 helicase) of HCV G3 using a combination of in silico and in vitro approaches. With the aid of SBVS, six novel compounds were discovered to inhibit HCV G3 NS3/4A protease and two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzopyrans
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Flavonoids

Share to Hepacivirus

Share to Molecular Docking Simulation

Share to Protease Inhibitors

Share to Viral Nonstructural Proteins

Share to Virus Replication

Source

Identifiers

PMID: 32657543
DOI: 10.1111/cbdd.13756

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational drug discovery: Ellagic acid as a potent dual-target inhibitor against hepatitis C virus genotype 3 (HCV G3) NS3 enzymes.PMID 32657543Read ↗

Structure-activity relationships of fluorene compounds inhibiting HCV variants.Semantic proximity Read ↗

Anti-hepatitis C virus and synergistic potential of Syzgium cumine a bioassay guided screening in liver-infected hepatocytes.Semantic proximity Read ↗

Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.Semantic proximity Read ↗

A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound.Semantic proximity Read ↗

2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.Semantic proximity Read ↗

Structure-based virtual screening of natural compounds against wild and mutant (R1155K, A1156T and D1168A) NS3-4A protease of Hepatitis C virus.Semantic proximity Read ↗

Docking studies of Pakistani HCV NS3 helicase: a possible antiviral drug target.Semantic proximity Read ↗

Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral InhibitorsSemantic proximity Read ↗

Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review.Semantic proximity Read ↗

Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.Semantic proximity Read ↗

Ligand and Structure Based Virtual Screening Strategies for Hit-Finding and Optimization of Hepatitis C Virus (HCV) InhibitorsSemantic proximity Read ↗

Rational Drug Discovery of HCV Helicase Inhibitor: Improved Docking Accuracy with Multiple Seeding in AutoDock Vina and In Situ Minimization.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.